

Correction

Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. *J. Clin. Med.* 2022, 11, 5828

Shun Kohsaka ¹ , Suguru Okami ², Naru Morita ² and Toshitaka Yajima ^{2,*}

¹ Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan

² Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan

* Correspondence: toshitaka.yajima@astrazeneca.com; Tel.: +81-6-4802-3600; Fax: +81-3-3457-9301

Error in Figure

In the original publication [1], there was a mistake in Figure 3 as published. Some prescription numbers and percentages in ACEi, ARB and MRA were wrong. The corrected Figure 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.




Figure 3. RAASi treatment according to dosage category (high, medium, or low) at the index date. Percentages were calculated using the total number of prescriptions. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; RAASi, renin–angiotensin–aldosterone system inhibitor.

Reference

1. Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. *J. Clin. Med.* **2022**, *11*, 5828. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T. Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. *J. Clin. Med.* **2022**, *11*, 5828. <https://doi.org/10.3390/jcm12072578>

Received: 16 March 2023
Accepted: 20 March 2023
Published: 29 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).